Bristol-Myers Squibb Company
NYSE: BMY
$58.74
-$0.04 (-0.1%)
Closing Price on November 26, 2024
BMY Articles
Bristol-Myers Squibb announced that the FDA has now extended the action date for the supplemental biologics license application for Opdivo in the war against advanced melanoma.
Published:
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
Published:
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
Published:
ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market...
Published:
Last Updated:
Bristol-Myers Squibb released better-than-expected second-quarter financial results before the markets opened Thursday.
Published:
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Published:
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Published:
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to...
Published:
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Published:
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
In a new report, the RBC team focused on the companies that are making the most progress with treatments for patients with breast cancer.
Published:
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
Published: